Interferon-independent STING enforces epithelial genome-integrity checkpoint to restrain tumor evolution

This study reveals that STING functions as an interferon-independent, cell-autonomous guardian of epithelial genome stability by regulating homologous recombination and ATM signaling to prevent chromosomal instability and tumor evolution, while its loss creates a selective vulnerability to CDK inhibition.

The Gist

The Big Picture: A Double-Edged Sword

Imagine your body's cells as a bustling city. Every day, the construction crews (DNA replication) are busy building new roads and houses. Sometimes, they make mistakes—like accidentally dropping a brick (DNA damage) or mixing up the blueprints.

Usually, there's a Security Guard named STING (Stimulator of Interferon Genes). For a long time, scientists thought STING's only job was to sound the alarm to the Police (the Immune System) when it saw a burglar (a virus or bacteria). Once the alarm was sounded, the police would come and fight the infection.

This paper discovers a new, hidden job for STING: It turns out that even when there are no burglars, STING is also the Chief Engineer inside the construction crew. It makes sure the blueprints are fixed correctly before the city expands. If STING is missing, the construction crew keeps building on top of mistakes, the city becomes chaotic (cancer), and the whole structure collapses.

---

The Story in Three Acts

Act 1: The Broken Blueprint (The Setup)

The researchers started with a specific problem in the gut (intestine). They used mice that were missing a tiny tool called RNase H2.

• The Analogy: Imagine RNase H2 is a "spell-checker" for the DNA. Without it, the construction crew keeps leaving typos in the DNA code.
• The Result: These typos pile up, creating "cytosolic DNA" (loose, broken pieces of DNA floating in the cell's cytoplasm).
• STING's Reaction: Normally, when STING sees this floating broken DNA, it panics. In these mice, STING was working overtime, trying to fix the mess. But the researchers wondered: Is STING actually helping fix the DNA, or is it just screaming for help?

Act 2: The Engineer Goes on Strike (The Discovery)

To find out, the researchers created a new group of mice: They took the mice with the broken spell-checker (RNase H2 missing) and removed STING as well.

• The Expectation: They thought removing STING might make things worse because the "alarm" wouldn't ring.
• The Shocking Reality: The mice without STING got cancer much faster and much more aggressively.
• The Metaphor: It's like taking away the Chief Engineer from a construction site that is already full of typos. Without the engineer, the workers didn't just stop; they started building faster but on top of the broken foundations. The buildings (cells) became unstable, twisted, and eventually turned into a chaotic slum (a tumor).

Key Finding: STING isn't just an alarm bell; it is a quality control inspector. It stops the cell from dividing if the DNA is broken, forcing the cell to fix the problem first. Without STING, the cell ignores the damage and keeps dividing, leading to chaos.

Act 3: The "Achilles' Heel" (The Solution)

Here is the most exciting part. The researchers asked: If these cancer cells are so chaotic and unstable because they lack STING, can we trick them into destroying themselves?

• The Problem: The cancer cells without STING were running on "high speed." They had a broken "brake pedal" (a checkpoint called the G2/M checkpoint). They were rushing into cell division even though their DNA was a mess.
• The Solution: The researchers used a drug called AZD5438, which acts like a brake pedal for the cell cycle.
• The Result: When they applied this "brake" to the STING-less cancer cells, the cells stopped dead. They couldn't handle the pressure of being fast and broken.
• The Analogy: Imagine a race car with no brakes and a cracked engine. If you try to drive it normally, it crashes. But if you have a special tool that locks the wheels (the drug), the car with the cracked engine explodes, while a normal car (healthy cells) just sits there fine.

The Takeaway: Cancers that have lost STING are "addicted" to moving fast. If you hit them with a drug that slows down cell division, they die. This gives doctors a new target for treating colorectal cancer.

---

Summary of the "Magic"

1. STING is a Guardian: It's not just for fighting viruses; it's essential for keeping our DNA stable in our gut cells.
2. No STING = Chaos: Without STING, cells ignore DNA damage, divide recklessly, and turn into tumors with twisted chromosomes (like a jigsaw puzzle with pieces from different boxes).
3. The Vulnerability: Because these STING-less tumors are so reckless, they are terrified of "brakes." Drugs that stop cell division (CDK inhibitors) work incredibly well on them, but not on healthy cells.

Why This Matters

This changes how we think about cancer. Instead of just trying to boost the immune system to fight cancer, we can look for tumors that have "lost their engineer" (STING). Once we find them, we can hit them with a specific "brake" drug that healthy cells don't need, killing the cancer while sparing the patient. It's a precision strike based on the tumor's own weakness.

Technical Summary

1. Problem Statement

The canonical role of the STING (Stimulator of Interferon Genes) protein is well-established as a cytosolic DNA sensor that activates the cGAS-STING pathway, leading to Type I Interferon (IFN-I) production and innate immune responses. However, the cell-intrinsic role of STING in maintaining genome stability within non-immune epithelial cells, independent of its immune signaling functions, remains unclear.

• Context: Failure of Ribonucleotide Excision Repair (RER), specifically via RNase H2 deficiency, leads to the accumulation of misincorporated ribonucleotides and subsequent DNA damage. This damage can result in cytosolic dsDNA accumulation, theoretically activating cGAS-STING.
• Gap: While cGAS has been linked to DNA repair modulation, the specific mechanism by which STING regulates DNA damage response (DDR) and genome integrity in the intestinal epithelium—and whether this occurs independently of IFN-I signaling—is unknown. Furthermore, the link between STING loss and spontaneous intestinal tumorigenesis driven by chromosomal instability (CIN) requires elucidation.

2. Methodology

The authors employed a multi-faceted approach combining genetic mouse models, cell biology, single-cell genomics, and pharmacological intervention:

• Genetic Models:
  • In Vivo: Generated mice with intestinal epithelial-specific deletion of Rnaseh2b (H2bΔIEC) to induce DNA damage. These were crossed with global Tmem173 (STING) knockouts (STING-/-) and epithelial-specific STING deletions (STINGΔIEC) to create H2bΔIEC/STING-/- and H2b/STINGΔIEC models.
  • In Vitro: Used the mouse intestinal epithelial cell line MODE-K to generate CRISPR/Cas9-mediated cGAS and STING knockouts.
• Genomic Analysis:
  • Strand-seq: Performed single-cell Strand-seq on intestinal organoids to quantify Sister Chromatid Exchanges (SCEs), breakpoints (BPs), and aneuploidies at single-cell resolution.
  • RNA-seq: Conducted transcriptomic profiling of organoids to identify dysregulated pathways and transcription factors.
• Molecular & Cellular Assays:
  • DDR Markers: Western blotting and immunofluorescence for γH2AX, p-ATM, p-TBK1, p21, and CDK1.
  • DNA Repair Efficiency: Used the DR-GFP reporter assay to measure Homologous Recombination (HR) efficiency.
  • Comet Assay: Quantified DNA strand breaks.
  • Co-Immunoprecipitation (Co-IP): Investigated physical interactions between ATM and the MRN complex (specifically NBS1).
  • Kinase Profiling: Used PamGene arrays to map serine/threonine and tyrosine kinase activity.
• Therapeutic Testing:
  • Treated tumor-derived organoids and human colorectal cancer (CRC) cell lines with the CDK inhibitor AZD5438 to assess sensitivity based on STING status.
  • Performed orthotopic transplantation of tumor organoids into immunodeficient NSG mice to test metastatic potential.

3. Key Contributions & Results

A. STING Loss Drives Spontaneous Intestinal Tumorigenesis

• Phenotype: While H2bΔIEC mice (RER deficient) showed some tumor development, the double-deficient H2bΔIEC/STING-/- mice exhibited a dramatic increase in spontaneous small intestinal adenocarcinomas (16/37 mice) compared to controls.
• Epithelial Intrinsic: Tumorigenesis was driven by epithelial STING loss, as confirmed by epithelial-specific deletion models (H2b/STINGΔIEC).
• Aggressiveness: These tumors were highly aggressive, capable of forming metastases in orthotopic transplant models.

B. STING is a Guardian of Genome Integrity (IFN-I Independent)

• Chromosomal Instability (CIN): Strand-seq revealed that STING loss in the context of DNA damage (H2bΔIEC) significantly increased the frequency of cells with high breakpoint burdens (>10 BPs/cell) and aneuploidies. Specifically, there was a marked enrichment of Trisomy 15 (harboring Myc and Rad21), suggesting clonal selection.
• Mechanism of Repair Failure:
  • STING deficiency impaired Homologous Recombination (HR) efficiency (DR-GFP assay).
  • It led to reduced ATM activation (phosphorylation at Ser1981) and diminished γH2AX signaling despite high levels of DNA breaks.
  • Mechanistic Insight: Co-IP showed that STING loss weakens the interaction between ATM and NBS1 (a component of the MRN complex), preventing efficient ATM recruitment to DNA damage sites.
  • IFN-I Independence: Exogenous IFN-β treatment or Ifnar1 knockdown did not rescue the DDR defects, confirming the role is IFN-I independent. The defect relies on the cGAS-STING axis up to TBK1 but is independent of IRF3-mediated transcription.

C. Disruption of the G2/M Checkpoint

• Checkpoint Failure: STING-deficient cells failed to arrest in G2/M upon DNA damage.
• Kinase Dysregulation: Kinase profiling and Western blots revealed:
  • Reduced p21 (a p53 target).
  • Elevated CDK1 activity and phosphorylation.
  • This imbalance forces cells with damaged DNA into mitosis, driving chromosomal instability.
• Specificity: This checkpoint defect was specific to STING loss; cGAS loss impaired ATM but did not fully reproduce the p21/CDK1 imbalance, suggesting STING has a unique role in checkpoint enforcement.

D. Therapeutic Vulnerability to CDK Inhibition

• Synthetic Lethality: The hyper-proliferative state driven by unchecked CDK1 activity in STING-deficient tumors created a therapeutic vulnerability.
• Sensitivity: STING-deficient tumor organoids and human CRC cell lines with low STING expression showed significantly higher sensitivity (lower IC50) to the CDK inhibitor AZD5438 compared to STING-proficient controls.
• Clinical Relevance: A negative correlation was observed between STING protein levels and sensitivity to CDK inhibition in human CRC cell lines.

4. Significance

• Repositioning STING: The study fundamentally redefines STING not just as an immune sensor, but as a cell-autonomous, IFN-I-independent guardian of epithelial genome stability. It acts upstream of ATM activation and HR repair.
• Mechanism of Tumorigenesis: It elucidates a specific pathway where RER failure $\rightarrow$ cGAS-STING sensing $\rightarrow$ ATM/NBS1 recruitment $\rightarrow$ G2/M checkpoint enforcement. Loss of this axis leads to CIN and spontaneous adenocarcinoma.
• Therapeutic Strategy: The findings identify CDK inhibition as a precision medicine strategy for STING-deficient tumors. This offers a potential solution to the toxicity issues of pan-CDK inhibitors by targeting the specific "CDK-addicted" state of STING-low tumors.
• Broader Implications: This work suggests that defects in genome maintenance can reprogram cell-cycle control to fuel oncogenic adaptation, providing a rationale for targeting cell-cycle checkpoints in tumors with compromised DNA damage response pathways.

Conclusion

The paper demonstrates that epithelial STING enforces a genome-integrity checkpoint independent of interferon signaling. Its loss impairs ATM-mediated DNA repair and G2/M checkpoint control, leading to chromosomal instability and spontaneous intestinal cancer. Crucially, this defect creates a selective vulnerability to CDK inhibition, offering a novel therapeutic avenue for STING-deficient colorectal cancers.